1. Home
  2. RMCF vs MRKR Comparison

RMCF vs MRKR Comparison

Compare RMCF & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rocky Mountain Chocolate Factory Inc.

RMCF

Rocky Mountain Chocolate Factory Inc.

N/A

Current Price

$1.77

Market Cap

27.2M

ML Signal

N/A

Logo Marker Therapeutics Inc.

MRKR

Marker Therapeutics Inc.

HOLD

Current Price

$1.45

Market Cap

24.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCF
MRKR
Founded
1981
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.2M
24.2M
IPO Year
2024
2010

Fundamental Metrics

Financial Performance
Metric
RMCF
MRKR
Price
$1.77
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
44.5K
56.3K
Earning Date
06-16-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
34.88
33.61
EPS
N/A
N/A
Revenue
$30,432,352.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$936.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$0.81
52 Week High
$2.99
$4.07

Technical Indicators

Market Signals
Indicator
RMCF
MRKR
Relative Strength Index (RSI) 27.61 45.96
Support Level $1.48 $1.35
Resistance Level $1.82 $1.52
Average True Range (ATR) 0.13 0.06
MACD -0.04 0.00
Stochastic Oscillator 2.11 22.73

Price Performance

Historical Comparison
RMCF
MRKR

About RMCF Rocky Mountain Chocolate Factory Inc.

Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).

Share on Social Networks: